Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice

The tumor necrosis factor type 1 death receptor (TNFR1) contributes to apoptosis. TNFR1, a subgroup of the TNFR superfamily, contains a cytoplasmic death domain. We recently demonstrated that the TNFR1 cascade is required for amyloid β protein (Aβ)–induced neuronal death. However, the function of TNFR1 in Aβ plaque pathology and amyloid precursor protein (APP) processing in Alzheimer's disease (AD) remains unclear. We report that the deletion of the TNFR1 gene in APP23 transgenic mice (APP23/TNFR1−/−) inhibits Aβ generation and diminishes Aβ plaque formation in the brain. Genetic deletion of TNFR1 leads to reduced β-secretase 1 (BACE1) levels and activity. TNFR1 regulates BACE1 promoter activity via the nuclear factor-κB pathway, and the deletion of TNFR1 in APP23 transgenic mice prevents learning and memory deficits. These findings suggest that TNFR1 not only contributes to neurodegeneration but also that it is involved in APP processing and Aβ plaque formation. Thus, TNFR1 is a novel therapeutic target for AD.

[1]  S. V. Anisimov,et al.  Congo red and protein aggregation in neurodegenerative diseases , 2007, Brain Research Reviews.

[2]  N. Bresolin,et al.  Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. , 2006, Archives of neurology.

[3]  Hung Li,et al.  Intracerebral Peripheral Blood Stem Cell (CD34+) Implantation Induces Neuroplasticity by Enhancing β1 Integrin-Mediated Angiogenesis in Chronic Stroke Rats , 2006, The Journal of Neuroscience.

[4]  J. Julien,et al.  Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.

[5]  R. Kayed,et al.  Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease , 2005, Journal of Neuroinflammation.

[6]  G. Stefano,et al.  Morphine via nitric oxide modulates beta-amyloid metabolism: a novel protective mechanism for Alzheimer's disease. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[7]  R. Morris,et al.  Conditional Inactivation of Presenilin 1 Prevents Amyloid Accumulation and Temporarily Rescues Contextual and Spatial Working Memory Impairments in Amyloid Precursor Protein Transgenic Mice , 2005, The Journal of Neuroscience.

[8]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[9]  G. Perry,et al.  β‐Site APP cleaving enzyme up‐regulation induced by 4‐hydroxynonenal is mediated by stress‐activated protein kinases pathways , 2005, Journal of neurochemistry.

[10]  T. Bayer,et al.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. , 2004, The American journal of pathology.

[11]  D. Wilcock,et al.  Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition , 2004, The Journal of Neuroscience.

[12]  Bryan Maloney,et al.  Gene structure and organization of the human β‐secretase (BACE) promoter , 2004 .

[13]  D. Storm,et al.  Overexpression of type-1 adenylyl cyclase in mouse forebrain enhances recognition memory and LTP , 2004, Nature Neuroscience.

[14]  L. Thal,et al.  Alzheimer disease without neocortical neurofibrillary tangles , 2004, Neurology.

[15]  H. Steinbusch,et al.  Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. , 2004, The American journal of pathology.

[16]  Dai Zhang,et al.  Tumor Necrosis Factor Death Receptor Signaling Cascade Is Required for Amyloid-β Protein-Induced Neuron Death , 2004, The Journal of Neuroscience.

[17]  Hong Qing,et al.  Transcriptional Regulation of BACE1, the β-Amyloid Precursor Protein β-Secretase, by Sp1 , 2004, Molecular and Cellular Biology.

[18]  L. Hersh,et al.  Substrate Activation of Insulin-degrading Enzyme (Insulysin) , 2003, Journal of Biological Chemistry.

[19]  D. Mann,et al.  Negative association between amyloid plaques and cerebral amyloid angiopathy in Alzheimer's disease , 2003, Neuroscience Letters.

[20]  O. Wiestler,et al.  Vascular Pathology in Alzheimer Disease: Correlation of Cerebral Amyloid Angiopathy and Arteriosclerosis/Lipohyalinosis with Cognitive Decline , 2003, Journal of neuropathology and experimental neurology.

[21]  D. Selkoe Aging, Amyloid, and Alzheimer's Disease: A Perspective in Honor of Carl Cotman , 2003, Neurochemical Research.

[22]  K. Blennow,et al.  Intrathecal inflammation precedes development of Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[23]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[24]  T. Tully,et al.  A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. H. Boo,et al.  Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. , 2003, Biochemical and biophysical research communications.

[26]  D. Bennett,et al.  Alzheimer disease in the US population: prevalence estimates using the 2000 census. , 2003, Archives of neurology.

[27]  Dave Morgan,et al.  Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation , 2003, The Journal of Neuroscience.

[28]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Mark A. Smith,et al.  Cerebral Hemorrhage and Amyloid-β , 2003, Science.

[30]  H. Tomizawa,et al.  Discovery of quinazolines as a novel structural class of potent inhibitors of NF-κB activation , 2003 .

[31]  R. D'Hooge,et al.  Age‐dependent cognitive decline in the APP23 model precedes amyloid deposition , 2003, The European journal of neuroscience.

[32]  Howard L. Weiner,et al.  Inflammation and therapeutic vaccination in CNS diseases , 2002, Nature.

[33]  G. Perry,et al.  Oxidative Stress Increases Expression and Activity of BACE in NT2 Neurons , 2002, Neurobiology of Disease.

[34]  Rachel Snow,et al.  A Second Look , 2002, Afterimage.

[35]  P. Hamet,et al.  Comparisons between C57BL/6J and A/J mice in motor activity and coordination, hole-poking, and spatial learning , 2002, Brain Research Bulletin.

[36]  Xin Wu,et al.  Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model , 2002, Nature Neuroscience.

[37]  Eric R. Kandel,et al.  Reversible Inhibition of CREB/ATF Transcription Factors in Region CA1 of the Dorsal Hippocampus Disrupts Hippocampus-Dependent Spatial Memory , 2002, Neuron.

[38]  Rena Li,et al.  Target Depletion of Distinct Tumor Necrosis Factor Receptor Subtypes Reveals Hippocampal Neuron Death and Survival through Different Signal Transduction Pathways , 2002, The Journal of Neuroscience.

[39]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[40]  C. Lemere,et al.  Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.

[41]  M. Staufenbiel,et al.  Spontaneous Hemorrhagic Stroke in a Mouse Model of Cerebral Amyloid Angiopathy , 2001, The Journal of Neuroscience.

[42]  B. Sommer,et al.  Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[44]  B. Sommer,et al.  Neuron loss in APP transgenic mice , 1998, Nature.

[45]  Yu-Min Kuo,et al.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. , 1998, The American journal of pathology.

[46]  V. Dixit,et al.  Death receptors: signaling and modulation. , 1998, Science.

[47]  B. Sommer,et al.  Aβ peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis , 1998, Molecular Psychiatry.

[48]  C. Ware,et al.  TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. , 1998, Journal of immunology.

[49]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Wozniak,et al.  A rotating holeboard procedure for testing drug effects on spatial learning and memory in mice. , 1997, Brain research. Brain research protocols.

[51]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[52]  D. Premkumar,et al.  Amyloid-β Protein Angiopathies Masquerading as Alzheimer's Disease?a , 1997 .

[53]  M. Mattson,et al.  Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors , 1996, Nature Medicine.

[54]  D. Borchelt,et al.  Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins , 1995, Neuron.

[55]  M. Mattson,et al.  Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Clark,et al.  Serotonergic Neuronal Properties in C-Cell Lines , 1995 .

[57]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[58]  J. Camonis,et al.  Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*) , 1995, The Journal of Biological Chemistry.

[59]  T. Miyatake,et al.  Cerebral amyloid angiopathy: A significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly , 1993, Journal of Neurological Sciences.

[60]  Mike Rothe,et al.  Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor , 1993, Cell.

[61]  R. Katzman.,et al.  Senile Dementia of the Alzheimer Type Without Neocortical Neurofibrillary Tangles , 1987, Journal of neuropathology and experimental neurology.

[62]  H. Vinters Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.

[63]  G. Gabbiani,et al.  A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation , 1986, The Journal of cell biology.

[64]  T. V. Van Dooren,et al.  Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice. , 2006, The American journal of pathology.

[65]  T. Klockgether,et al.  Nonsteroidal anti-inflammatory drugs repress (cid:1) -secretase gene promoter activity by the activation of PPAR (cid:2) , 2005 .

[66]  V. Mathura,et al.  Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. , 2005, Journal of neuroinflammation.

[67]  P. Wong,et al.  Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease , 2003, Nature Medicine.

[68]  J. Kornhuber,et al.  Improved electrophoretic separation and immunoblotting of beta‐amyloid (Aβ) peptides 1–40, 1–42, and 1–43 , 1997, Electrophoresis.

[69]  L. Hersh,et al.  [16] Neprilysin: Assay methods, purification, and characterization , 1995 .

[70]  Jo Garcia Sharing research results with patients: the views of care-givers involved in a randomized controlled trial. , 1987, Journal of reproductive and infant psychology.

[71]  Rena Li,et al.  Amyloid (cid:1) peptide load is correlated with increased (cid:1) -secretase activity in sporadic Alzheimer’s disease patients , 2004 .